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Objective: In this study we analyzed claims data from the Ingenix database to analyze 
outcomes of sacral neuromodulation with respect to both provider and patient factors.  
Materials and Methods: We used the Ingenix (I3) database to determine demographic, 
diagnosis, and procedure success information for years 2002-2007 for privately insured 
patients. Demographic information was obtained, as were the diagnoses given and 
procedures performed, based on ICD-9 diagnosis codes and CPT procedure codes.  
Multivariate analysis was performed to identify specific predictors of success, as 
measured by progression to implantation of a pulse generator.  
Results: Overall success, as defined by battery placement, was 49.1%.  Fifty-one percent 
of staged procedures were followed by battery placement compared with 24.1% of 
percutaneous cases (p<0.0001). Among the patient variables analyzed, women were more 
likely than men to progress to battery placement.  After Stage I testing, patients treated by 
urologists were overall more likely than gynecologists to proceed to battery placement 
(I3: 54% vs. 47%, p < 0.0001).  Unlike previous findings in other claims-based data sets, 
we did not observe a provider-volume relationship in the i3 dataset. 
Conclusions: Success of sacral neuromodulation, as defined by proceeding to battery 
placement, was much better after formal staged procedures, which leads us to question 
the utility of percutaneous techniques. Outcomes were also better among female patients 
and among those treated by a urologist. Specialty differences will likely diminish over 
time as more gynecologists adopt sacral neuromodulation.  
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 Sacral neuromodulation has demonstrated efficacy in the treatment of many 
chronic urological diseases refractory to medical therapy, including overactive bladder 
symptoms, urinary retention, neurogenic voiding dysfunction, and even interstitial 
cystitis. More recently, sacral neuromodulation has been FDA-approved and proven 
effective for the treatment of fecal incontinence
1
. Once an invasive procedure involving a 
large incision over the sacrum, in 2001 the device was modified such that is it now a 
minimally invasive procedure that is often performed under local anesthesia with 
intravenous sedation. Patients typically undergo a one or two week testing period to 
determine whether there is an adequate symptom response (usually defined as a 50% or 
greater improvement in symptoms
2
) before proceeding to battery placement.  Testing is 
either performed with a permanent lead (formal stage I, often under sedation) or a 
temporary wire (Peripheral Nerve Evaluation, PNE, usually in the office) which is 
replaced with the permanent lead and battery after the testing period
3
.   
 Previous studies, both clinical and claims-based, have identified patient factors 
associated with outcomes of sacral neuromodulation. Variables associated with improved 
outcomes include female gender, younger age, and a diagnosis of OAB over other types 
of voiding dysfunctions
3
. However, relatively little is known about the effect of surgeon 
variables on outcomes of neuromodulation, such as surgeon volume, or case load, and 
surgeon subspecialty (urology vs. gynecology). Use of claims-based data is an ideal 
means to measure such surgeon factors in a heterogeneous, broadly distributed 
population. 
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At that time we analyzed outcomes of sacral neuromodulation in two claims-
based datasets, Medicare and I3 (Ingenix)
3
.  We next analyzed specific provider and 
patient factors affecting outcomes of sacral neuromodulation in the Medicare population
4
. 
Herein we used the I3 dataset to measure variables that may affect outcomes of 
neuromodulation in a younger, privately insured population, whose outcomes may differ 
from that of the Medicare population. We specifically analyzed provider specialty and 
volume, and patient factors including age, gender, race, and chief urologic diagnosis.  
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Materials and Methods 
 The Ingenix (I3) database includes nationwide claims for the employees of 25 
large companies (Fortune 500) and their dependents. The Ingenix (I3) database was used 
to determine demographic, diagnosis, and procedure success information for years 2002-
2007 for these privately insured patients.  Since all patient data were de-identified, this 
work was granted an Institutional Review Board exemption from UCLA and RAND 
Corporation. This time frame was specifically chosen in order for us to make 
comparisons to our previously conducted work in the Medicare population during a 
similar time period
3
. Current Procedural Terminology, 4
th
 edition (CPT-4) codes were 
used to identify procedures performed on each individual, and ICD-9 diagnosis codes 
were used to identify the clinical indication, as previously described
3
. Patients were 
assigned a diagnosis of OAB-dry if they carried one or more of the following codes: 
urgency of urination (ICD-9 code 788.63), urinary frequency (788.41), bladder 
hypertonicity (596.51), detrusor instability (596.59), or nocturia (788.43) and did not 
meet any of the criteria for OAB-wet. They were assigned a diagnosis of OAB-wet if 
they had a code for unspecified urinary incontinence (788.30), urge incontinence 
(788.31), and/or mixed incontinence (788.33).  Patients were also assigned a diagnosis of 
neurogenic voiding dysfunction, interstitial cystitis, or “other” voiding dysfunction 
categories, based on relevant ICD-9 codes
3
.  
 Lead placement was either performed as a percutaneous placement (CPT-4 code 
64561) or an operative lead placement (Stage I, CPT-4 code 64581). Because of our 
inability to accurately measure detailed clinical outcomes, such as symptom severity or 
bother, in claims-based datasets, we defined success as proceeding to battery 
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implantation (CPT-4 code 64590). This assumes that patients who went on to battery 
placement met criteria for significant improvement, usually 50% or greater improvement 
in symptoms
5
. We compared outcomes by provider volume and specialty (urology vs. 
gynecology). We defined a high volume provider as one who performed in the upper 25
th
 
percentile of procedures performed. This corresponded to 30+ procedures over the 2002-
2007 time period. Descriptive statistics were used to report success rates, as defined by 
battery placement. Patient factors analyzed included age, gender, race, and chief 
diagnosis for which sacral neuromodulation was performed. Multivariate analysis was 
performed to identify predictors of outcome while controlling for covariates. The chi-
square test was used to compare success and failure rates based on patient and provider 
variables. Statistical analysis was performed with the Statistical Analysis System 
(SAS®). 
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 In the I3 population, 794 two-stage procedures and 266 percutaneous procedures 
were performed from 2002 to 2007. As previously described, the sample was 81.3% 
female and 62.7% Caucasian
3
. The majority of patients were younger than 65 years old 
(82.2%).  OAB was the most common indication for the procedure, followed by urinary 
retention, IC, and “other” diagnoses
3
. Overall success, as defined by battery placement, 
was 49.1%.  Fifty-one percent of staged procedures were followed by battery placement 
compared with 24.1% of percutaneous cases (p<0.0001)
3
.  
 The top volume quartile of providers was at least 30 cases in 5 years.  Physicians 
in the top quartile performed 84.3% of cases (242 percutaneous trials and 652 operative 
trials) and those in the lower three quartiles performed 15.7% of cases (24 percutaneous 
trials an  142 operative trials).  The rate of progression to battery placement was 
significantly different for the top quartile vs. the lower three quartiles (I3, Table 1). 
However, in multivariate analysis (Table 2), surgeon volume was not a significant 
predictor of outcomes.  
 Seventy-three percent of cases were performed by urologists (197 percutaneous 
trials and 572 operative) and 17.0% were performed by gynecologists (31 percutaneous 
trials and 149 operative trials). Urologists had higher rates of battery placement after 
operative trials than gynecologists (I3: 54% vs. 47%, p < 0.0001).  Multivariate analysis 
confirmed a higher rate of battery placement for two-staged procedures (OR 2.8, 95% CI 
2.0-3.9, Table 2) and overall among urologists (OR 2.3, 95% CI 1.7-3.1, Table 2).  
 Success rates were greater among female patients than male patients (51.5% vs. 
38.5%, p<0.0001). In fact, multivariate analysis confirmed a nearly two-fold difference in 
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outcomes between men and women for both two-staged procedures (OR 1.6, 95% CI 1.1-
2.5, Table 2) and overall (OR 2.0, 95% CI 1.4-2.8, Table 2). Patient age, however, did not 
have a significant impact on outcomes. Those with a diagnosis of neurogenic bladder had 
worse overall outcomes than OAB-wet (OR 0.4, 95% CI 0.2-0.7, Table 2). For the subset 
undergoing percutaneous testing, those with OAB-dry actually had a higher rate of 
battery placement than those with OAB-wet (OR 2.2, 95% CI 1.0-4.5, Table 2). 
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Our findings in I3 demonstrate worse outcomes in the “real world” as compared 
to data from clinical series, usually conducted by high-volume experts in the field. Fifty-
one percent of staged procedures were followed by battery placement compared with 
24.1% of percutaneous cases (p<0.0001).  These findings demonstrate a drastic difference 
in outcomes between the two techniques.  These findings of relatively poor outcomes 
overall are consistent with our prior work in Medicare from the same time frame, in 
which 46% of the percutaneous tests and 35% of the staged tests resulted in placement of 
a permanent battery.  However, patients in the I3 dataset had superior outcomes with 
staged testing and inferior outcomes than Medicare beneficiaries with percutaneous 
testing. These findings are also consistent with clinical series in the literature
6, 7
. Given 
that the outcomes of formal stage 1 testing are so much better across both claims-based 
datasets and clinical series, our findings lead us to question the utility of percutaneous 
testing as an effective treatment modality,  
We also identified a relationship between provider and patient variables and 
success rates in I3, as measured by proceeding to battery implantation.  Patients who 
underwent lead placement by a urologist were more likely to proceed to battery 
placement. In our previous analysis of Medicare data, urologists were more likely than 
gynecologists to proceed to battery placement after operative lead placement (49% vs. 
43%, p < 0.0001), but gynecologists were more likely than urologists to proceed to 
battery placement after percutaneous testing (63% vs.44%, p = 0.005). The provider-
specialty relationship is difficult to define with sacral neuromodulation, since success, as 
defined by permanent battery placement, is a function of both surgeon and patient 
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decision-making. The majority of lead placements in both datasets were performed by 
urologists. The fact that outcomes were better among urologists may be due to that fact 
that there were more high volume providers, including more fellowship-trained providers, 
among urologists than gynecologists in the I3 dataset. Alternatively, urologists may have 
used less stringent definitions of success in deciding to proceed to stage II. 
Female patients had better outcomes than males, a relationship that was also 
shown in Medicare and in previous case series
3
. Possibly the presence of a prostate and 
associated outlet obstruction of varying degrees could result in more treatment-refractory 
bladder conditions. Outcomes were also worse among those with neurogenic bladder, a 
finding also supported in the literature
6
. What is not consistent with the literature and our 
prior work with Medicare is the finding that, in the subset of I3 patients undergoing 
percutaneous testing, patients with OAB-dry were more likely to proceed with battery 
placement than those with OAB-wet. Most large series show improved outcomes in the 
OAB-wet population. Possible explanations for this inconsistency could be the inherent 
inaccuracies in ICD-9 coding of symptoms, meaning that the populations were not 
actually pure OAB-dry and OAB-wet.  In addition, the sample size of the group who 
underwent percutaneous testing was small; therefore a larger sample size may have found 
different relationships between urologic diagnoses and outcomes.  
The strong provider-volume relationship we previously observed in Medicare was 
not demonstrated in the I3 dataset
4
. However, the majority of cases in I3 were performed 
by high volume providers, which may have contributed to better outcomes overall in I3. 
Also, we arbitrarily defined a high volume provider as those performing in the upper 
quartile of providers, a technique used previously by us and others
8
. The upper quartile of 
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providers in I3 was actually much higher volume than it was in the Medicare population 
(30 cases over 6 years vs. 5 cases over eleven years in CMS), indicating that many 
providers in I3 who fell under the 75
th
 percentile were still relatively high volume 
providers. This might be explained by the possibility that, once physicians complete a 
learning curve, provider volume may have less of an influence on progression to battery 
placement. In addition, the I3 population was younger than the Medicare population, and 
therefore may have demonstrated better outcomes regardless of volume-related provider 
differences. The younger age of the I3 population may also explain the fact that we did 
not find a significant impact of patient age on outcomes, as the number of older adults in 
this population was smaller than that in Medicare.  
 Our work is among the few claims-based analyses of sacral neuromodulation 
outcomes using a national dataset. Such analyses shed light into real-world practice 
patterns in a large, heterogeneous population. However, this work does have limitations. 
Inherent in claims-based data is a lack of clinical detail. Specifically, we did not have 
information about degree of improvement and reasons for not proceeding with a staged 
procedure after a failed PNE. We therefore had to make assumptions that doctors would 
only proceed to stage 2 if patients were significantly better. However, this was likely the 
case for the vast majority of patients. Although we chose this dataset in order to make 
comparisons to Medicare analyses from the same time frame, more recent data might 
reflect different practice patterns than what we found in 2002-2007; however, there have 
been no major changes in surgical techniques since this time period, other than the  
recently developed curved stylet. Possibly future studies will demonstrate better 
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outcomes with this new modification. We also lacked information on fellowship training, 
which likely influenced outcomes. 
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 Success of sacral neuromodulation, as defined by implantation of a permanent 
battery, was greater among women in the I3 dataset than in Medicare, though there was 
variation in outcomes by patient diagnosis. This suggests that technical factors, including 
the use of an operative (staged) testing approach, play a role in improving outcomes. 
Further research may better define the relationship between outcomes of sacral 
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Success of Sacral neuromodulation in I3, 2002-2007   
 

































































































































Total: 266 24.1 54.1 13.2 8.6  794 50.9 44.7  49.1 
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(no perc)    
Overall 
Success   
 Odds Ratio 95% CI  
Odds 
Ratio 95% CI  
Odds 
Ratio 95% CI 
High Surgeon 
volume (vs. 
low) 0.918 0.471 1.788  1.086 0.776 1.520  1.061 0.791 1.423 
Urologist (vs. 
gynecologist) 0.882 0.449 1.731  2.790 1.981 3.929  2.311 1.713 3.117 
White (vs. 
non-white) 
patient 0.647 0.355 1.180  1.073 0.793 1.453  1.159 0.891 1.508 
Female (vs. 
male) 1.498 0.718 3.125  1.632 1.077 2.474  1.986 1.404 2.808 
Age 55 or less 




group) 1.000    1.000    1.000   
Diagnosis 
NGB (vs. Wet 
OAB) 0.221 0.027 1.818  0.497 0.237 1.043  0.383 0.200 0.731 
Diagnosis IC 
(vs. Wet 
OAB) 1.510 0.536 4.250  1.092 0.599 1.990  1.142 0.686 1.900 
Diagnosis 
retention (vs.  
Wet OAB) 1.199 0.460 3.130  0.923 0.589 1.447  1.079 0.726 1.603 
Diagnosis dry 
OAB (vs.  
Wet OAB) 2.159 1.029 4.532  1.010 0.716 1.425  1.027 0.759 1.389 
Table 2. Multivariate Analysis of Outcomes based on Provider and Patient Variables 
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Success of Sacral neuromodulation in I3, 2002-2007   
 

































































































































Total: 266 24.1 54.1 13.2 8.6  794 50.9 44.7  49.1 
Table 1. Success of Sacral Neuromodulation by Provider Volume and Specialty 
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